CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting Phase 3 chronic constipation clinical trial results for linaclotide, an investigational guanylate cyclase type-C (GC-C) agonist for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans from May 1 through May 5, 2010. Ironwood and Forest released the top-line results from the CC trials late last year and expect to have data from the Phase 3 IBS-C trials in the second half of 2010.
